MedicalMinute: Listening to the Patient’s Perspective on IBD

Review best practices of shared-decision making and discussing risk of cancer when discussing initiation of biologic therapy with patients who have IBD.
Millie D. Long, MD, MPH, FACG, AGAF
Format: Microsoft PowerPoint (.ppt)
File Size: 784 KB
Released: June 24, 2021

Acknowledgements

Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Bristol-Myers Squibb

Related Content

Clinical Care Options (CCO) presents expert commentary on new data in Crohn disease and ulcerative colitis from ECCO 2022

Bruce E. Sands, MD, MS Released: May 13, 2022

Expert slides from Clinical Care Options (CCO) on new data from ECCO 2022 17th Congress Meeting in patients with Crohn disease and ulcerative colitis

Uma Mahadevan, MD Bruce E. Sands, MD, MS Released: May 6, 2022

Expert commentary on the role of HLA-DQA1*05 in patients with IBD receiving anti-TNF therapy, from Clinical Care Options (CCO)

Marla Dubinsky, MD Bruce E. Sands, MD, MS Released: March 2, 2022

Expert commentary on monitoring antidrug antibodies in patients with IBD receiving anti-TNF therapy, from Clinical Care Options (CCO)

Marla Dubinsky, MD Bruce E. Sands, MD, MS Released: February 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings